Non-alcoholic Fatty Liver Disease and Its Treatment
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Dipeptidyl peptidase-4 inhibitors (DPP-4I), key regulators of the actions of incretin
hormones, exert anti-hyperglycemic effects in type 2 diabetes mellitus (T2DM) patients. A
major unanswered question concerns the potential ability of DPP-4I to improve intrahepatic
lipid (IHL) content in nonalcoholic fatty liver disease (NAFLD) patients. The aim of this
study was to evaluate the effects of sitagliptin on IHL in NAFLD patients.